CMRA | Jotup

Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

Retrieved on:

Monday, November 13, 2023

CMRA, Johnson & Johnson, Safety, Partnership, Pharmaceutical industry

WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors.

Key Points:

WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors.
“Dorothy’s extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.
Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compliance and data protection functions.
“I believe Comera’s SQore platform holds significant potential for partnership and pipeline opportunities and I look forward to working with the leadership team and my fellow Board members to advance Comera’s growth and corporate strategy,” Ms. Clarke said.

Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

Retrieved on:

Thursday, November 9, 2023

Excipient, Biotechnology, Regeneron Pharmaceuticals, European Journal of Pharmaceutical Sciences, Research, Journal, CMRA, Pharmacy, European Patent Office, Partnership, GMP, Safety, European Patent Convention, Caffeine, Pharmaceutical industry, Security (finance), Vaccine, Cryptocurrency

WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points:

“Comera continues to generate significant momentum, by expanding our patent portfolio, strengthening our cash position and advancing key partnerships.
The partnership includes a right to negotiate a license after the technical evaluation is complete.
Technical evaluation is expected to be completed in Q4 2023.
Comera had approximately $1.8 million in cash at September 30, 2023.

Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference

Retrieved on:

Monday, October 16, 2023

Denaturation, Ipilimumab, CMRA, James Alfred Dunn Podd, Mab, Safety, Pharmacy, SQ, Journal, Caffeine, Hook effect, Aggregation, Excipient, Research, Journal of Pharmaceutical Sciences, Vaccine

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.

Key Points:

WOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass.
Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera’s SQore platform which is designed to transform intravenous biologics such as monoclonal antibodies (mAbs) into subcutaneous (SQ) formulations.
Comera’s SQore platform has been successfully tested with over 40 mAbs, with viscosity reductions of up to 85%.
Comera uses the SQore platform to identify the driving forces for high viscosity and select excipients that inhibit attractive protein-protein interactions to lower viscosity.

Comera Life Sciences Announces the Completion of $4.1 Million Private Placement

Retrieved on:

Tuesday, September 12, 2023

CMRA, Security (finance), Bangladesh Securities and Exchange Commission, Exchange, Safety, Sale

The shares are accompanied by five-year warrants to purchase shares of common stock at an exercise price of $0.6135 per share.

Key Points:

The shares are accompanied by five-year warrants to purchase shares of common stock at an exercise price of $0.6135 per share.
On July 31, 2023, Comera sold and issued a total of 4,399,016 shares of its common stock and warrants to purchase an aggregate of 10,997,550 shares of its common stock in a first closing, resulting in gross proceeds of $2.25 million to Comera.
Proceeds from the private placement are expected to be used for working capital and general corporate purposes.
Concurrently with the initial closing, Comera and the investors entered into a registration rights agreement pursuant to which the Company has filed a registration statement with the Securities and Exchange Commission registering the resale of the securities sold in the private placement.

Comera Life Sciences Announces Publication of Study Reinforcing Caffeine’s Viscosity Reducing Capabilities

Retrieved on:

Wednesday, August 16, 2023

PK, Pharmacy, Caffeine, Absorption, Indian Journal of Pharmaceutical Sciences, CMRA, Journal, Ipilimumab, Irritation, Mab, Protein engineering, SQ, Safety, Vaccine

WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine’s viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formulations of monoclonal antibodies.

Key Points:

WOBURN, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine’s viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formulations of monoclonal antibodies.
These studies aimed to assess the pharmacokinetic (PK) characteristics of caffeine and its influence on the PK behavior of a representative monoclonal antibody (mAb) ipilimumab.
The outcomes show rapid SQ absorption and elimination of caffeine, regardless of whether it was administered alone or in conjunction with the monoclonal antibody.
“This study is an important validation of caffeine’s potential to address critical viscosity challenges in developing subcutaneous biologics,” said Robert Mahoney, Ph.D., Chief Scientific Officer of Comera.

Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

Retrieved on:

Thursday, August 10, 2023

GMP, Partnership, Regeneron Pharmaceuticals, Biotechnology, European Patent Office, Research, CMRA, Excipient, Patent, European Patent Convention, Safety, Pharmaceutical industry, Security (finance), Cryptocurrency, Generic drug, Fine chemical

WOBURN, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Key Points:

The partnership includes an option to negotiate a license after the technical evaluation is complete.
On August 8, 2023, received formal notice that Nasdaq granted Comera’s request for the continued listing of its common stock, subject to Comera’s satisfaction of certain conditions.
Comera is taking definitive steps to comply with these conditions; however, there can be no assurance that it will be able to do so.
Comera had approximately $0.8 million in cash and accounts receivables, at June 30, 2023.

Comera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ Platform

Retrieved on:

Tuesday, August 8, 2023

Partnership, Hook effect, Caffeine, CMRA, Excipient, Patent, Mab, Safety, Pharmaceutical industry, Generic drug

The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera’s SQore platform and significantly broaden claims covered by previously issued patents.

Key Points:

The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera’s SQore platform and significantly broaden claims covered by previously issued patents.
The addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations.
The new issuances and allowed patents broaden the number of SQore excipients covered for viscosity reduction claims, including exclusive rights to certain formulations containing combinations of its proprietary excipients.
Today’s announcement also marks the first issued patent in India, validating Comera’s efforts to ensure a broad geographic scope for SQore patent protection.

Comera Life Sciences Announces $4.1 Million Private Placement

Retrieved on:

Tuesday, August 1, 2023

CMRA, Sale, Security (finance), Quality of life, Bangladesh Securities and Exchange Commission, Exchange, Safety

WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share.

Key Points:

WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share.
On July 31, 2023, Comera sold and issued a total of 4,399,016 shares of its common stock and warrants to purchase an aggregate of 10,997,550 shares of its common stock in a first closing, resulting in gross proceeds of $2.25 million to Comera.
Proceeds from the private placement are expected to be used for working capital and general corporate purposes.
Concurrently with the closing, Comera and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities sold in the private placement.

Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients

Retrieved on:

Thursday, July 20, 2023

GMP, Partnership, QCL, CMRA, Science, Excipient, Safety, Pharmaceutical industry

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture one of Comera’s lead SQore™ excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company.

Key Points:

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture one of Comera’s lead SQore™ excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company.
“In addition to the substantial investment we have made in the science behind our proprietary SQore platform, we are building value by expanding our SQore patent portfolio and ensuring supply and access to our lead SQore excipients,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.
“There has been a growing trend towards bringing back manufacturing of critical, high-value technologies such as pharmaceuticals to the United States to reduce supply risk, ensure high quality production and improve regulatory compliance.
Comera’s proprietary SQore platform integrates computational modeling, a robust library of excipients, and advanced formulation engineering to expedite the development of patient-preferred biotherapeutic formulations, while fostering novel intellectual property creation.

Esri Technology Powers The Washington Post’s “Heat Tracker”

Retrieved on:

Wednesday, July 12, 2023

United by a shared commitment to using open information to help better understand the world, The Washington Post, the Pulitzer Prize-winning capital-based news organization, and Esri , the global leader in geographic information system (GIS) technology, have joined to bring readers a US “Heat Tracker” as part of its climate reporting.

Key Points:

United by a shared commitment to using open information to help better understand the world, The Washington Post, the Pulitzer Prize-winning capital-based news organization, and Esri , the global leader in geographic information system (GIS) technology, have joined to bring readers a US “Heat Tracker” as part of its climate reporting.
“At Esri, we support the journalistic mission of The Washington Post to inform the public and world about critical issues and we believe science, geography, and data can illuminate many of the world’s most daunting problems,” said Jack Dangermond, Esri founder and president.
“The Washington Post is committed to immersive storytelling and providing our audience with new ways to understand news and complex issues,” said Evan Bretos, Director of Special Initiatives and Partnerships for The Washington Post.
“By engaging in this timely collaboration, we hope to showcase the best of our collective expertise in ways that we are excited to accomplish with The Washington Post.”